scholarly journals Remote ischemic preconditioning delays the onset of acute mountain sickness in normobaric hypoxia

2015 ◽  
Vol 3 (3) ◽  
pp. e12325 ◽  
Author(s):  
Marc M. Berger ◽  
Hannah Köhne ◽  
Lorenz Hotz ◽  
Moritz Hammer ◽  
Kai Schommer ◽  
...  
2017 ◽  
Vol 123 (5) ◽  
pp. 1228-1234 ◽  
Author(s):  
Marc M. Berger ◽  
Franziska Macholz ◽  
Lukas Lehmann ◽  
Daniel Dankl ◽  
Marcel Hochreiter ◽  
...  

Remote ischemic preconditioning (RIPC) has been shown to protect remote organs, such as the brain and the lung, from damage induced by subsequent hypoxia or ischemia. Acute mountain sickness (AMS) is a syndrome of nonspecific neurologic symptoms and in high-altitude pulmonary edema excessive hypoxic pulmonary vasoconstriction (HPV) plays a pivotal role. We hypothesized that RIPC protects the brain from AMS and attenuates the magnitude of HPV after rapid ascent to 3,450 m. Forty nonacclimatized volunteers were randomized into two groups. At low altitude (750 m) the RIPC group ( n = 20) underwent 4 × 5 min of lower-limb ischemia (induced by inflation of bilateral thigh cuffs to 200 mmHg) followed by 5 min of reperfusion. The control group ( n = 20) underwent a sham protocol (4 × 5 min of bilateral thigh cuff inflation to 20 mmHg). Thereafter, participants ascended to 3,450 m by train over 2 h and stayed there for 48 h. AMS was evaluated by the Lake Louise score (LLS) and the AMS-C score. Systolic pulmonary artery pressure (SPAP) was assessed by transthoracic Doppler echocardiography. RIPC had no effect on the overall incidence (RIPC: 35%, control: 35%, P = 1.0) and severity (RIPC vs. control: P = 0.496 for LLS; P = 0.320 for AMS-C score) of AMS. RIPC also had no significant effect on SPAP [maximum after 10 h at high altitude; RIPC: 33 (SD 8) mmHg; controls: 37 (SD 7) mmHg; P = 0.19]. This study indicates that RIPC, performed immediately before passive ascent to 3,450 m, does not attenuate AMS and the magnitude of high-altitude pulmonary hypertension. NEW & NOTEWORTHY Remote ischemic preconditioning (RIPC) has been reported to improve neurologic and pulmonary outcome following an acute ischemic or hypoxic insult, yet the effect of RIPC for protecting from high-altitude diseases remains to be determined. The present study shows that RIPC, performed immediately before passive ascent to 3,450 m, does not attenuate acute mountain sickness and the degree of high-altitude pulmonary hypertension. Therefore, RIPC cannot be recommended for prevention of high-altitude diseases.


2015 ◽  
Vol 3 (8) ◽  
pp. e12498
Author(s):  
Marc M. Berger ◽  
Hannah Köhne ◽  
Lorenz Hotz ◽  
Moritz Hammer ◽  
Kai Schommer ◽  
...  

2021 ◽  
Author(s):  
Kaitlyn G. DiMarco ◽  
Kara M. Beasley ◽  
Karina Shah ◽  
Julia P. Speros ◽  
Jonathan E. Elliott ◽  
...  

2019 ◽  
Vol 20 (1) ◽  
pp. 61-70 ◽  
Author(s):  
Alexander Patrician ◽  
Michael M. Tymko ◽  
Hannah G. Caldwell ◽  
Connor A. Howe ◽  
Geoff B. Coombs ◽  
...  

2011 ◽  
Vol 300 (2) ◽  
pp. R428-R436 ◽  
Author(s):  
Charles S. Fulco ◽  
Stephen R. Muza ◽  
Beth A. Beidleman ◽  
Robby Demes ◽  
Janet E. Staab ◽  
...  

There is an expectation that repeated daily exposures to normobaric hypoxia (NH) will induce ventilatory acclimatization and lessen acute mountain sickness (AMS) and the exercise performance decrement during subsequent hypobaric hypoxia (HH) exposure. However, this notion has not been tested objectively. Healthy, unacclimatized sea-level (SL) residents slept for 7.5 h each night for 7 consecutive nights in hypoxia rooms under NH [ n = 14, 24 ± 5 (SD) yr] or “sham” ( n = 9, 25 ± 6 yr) conditions. The ambient percent O2 for the NH group was progressively reduced by 0.3% [150 m equivalent (equiv)] each night from 16.2% (2,200 m equiv) on night 1 to 14.4% (3,100 m equiv) on night 7, while that for the ventilatory- and exercise-matched sham group remained at 20.9%. Beginning at 25 h after sham or NH treatment, all subjects ascended and lived for 5 days at HH (4,300 m). End-tidal Pco2, O2 saturation (SaO2), AMS, and heart rate were measured repeatedly during daytime rest, sleep, or exercise (11.3-km treadmill time trial). From pre- to posttreatment at SL, resting end-tidal Pco2 decreased ( P < 0.01) for the NH (from 39 ± 3 to 35 ± 3 mmHg), but not for the sham (from 39 ± 2 to 38 ± 3 mmHg), group. Throughout HH, only sleep SaO2 was higher (80 ± 1 vs. 76 ± 1%, P < 0.05) and only AMS upon awakening was lower (0.34 ± 0.12 vs. 0.83 ± 0.14, P < 0.02) in the NH than the sham group; no other between-group rest, sleep, or exercise differences were observed at HH. These results indicate that the ventilatory acclimatization induced by NH sleep was primarily expressed during HH sleep. Under HH conditions, the higher sleep SaO2 may have contributed to a lessening of AMS upon awakening but had no impact on AMS or exercise performance for the remainder of each day.


2020 ◽  
Vol 106 (1) ◽  
pp. 175-190
Author(s):  
Holly Barclay ◽  
Saptarshi Mukerji ◽  
Bengt Kayser ◽  
Terrence O'Donnell ◽  
Yu‐Chieh Tzeng ◽  
...  

2014 ◽  
Vol 75 (6) ◽  
pp. 890-898 ◽  
Author(s):  
Justin S. Lawley ◽  
Noam Alperin ◽  
Ahmet M. Bagci ◽  
Sang H. Lee ◽  
Paul G. Mullins ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document